LivaNova sponsored and funded the studies in ... The population studied “was probably the sickest group of treatment-resistant depression patients ever studied,” said Conway, who was also ...

The researchers found that the percent time in Montgomery-Åsberg Depression Rating Scale response ... and medical technology companies, including LivaNova; LivaNova funded the original study ...

LivaNova (LIVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from ...

Therapeutic breakthroughs in neuromodulation merge wearable technologies, deep brain implants, and tailored stimulations ...

LONDON, January 21, 2025--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 ...

LivaNova undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances. The views and opinions expressed herein are ...

Barclays analyst Matt Miksic lowered the firm’s price target on LivaNova (LIVN) to $58 from $61 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical technology outlook ...

LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting ...

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m.

LivaNova’s LIVN OSPREY trial, evaluating the aura6000 nerve stimulation system for obstructive sleep apnea (OSA), has delivered promising results.By meeting primary safety and efficacy endpoints ...